AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals to Webcast Update on SYMLIN(R) Regulatory Status SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will webcast an update on the regulatory status of SYMLIN(R) (pramlintide acetate) on Monday, September 20, 2004 at 12:00 p.m. ET (9:00 a.m. PT). SYMLIN(R) is currently under review with the FDA for the treatment of people with type 1 and insulin-using type 2 diabetes. Ginger L. Graham, President and Chief Executive Officer of Amylin Pharmaceuticals, will lead the call. The call will be webcast live through Amylin's corporate website, and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com/ approximately fifteen minutes prior to the call to register, download and install any necessary audio software. A recording will be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 61201960. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic diseases through the discovery, development and commercialization of innovative, cost-effective medicines. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright